RT Journal Article
SR Electronic
T1 Silent Hypoxia in Coronavirus disease-2019: Is it more dangerous?-A retrospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.26.21262668
DO 10.1101/2021.08.26.21262668
A1 Sirohiya, Prashant
A1 Elavarasi, Arunmozhimaran
A1 Raju Sagiraju, Hari Krishna
A1 Baruah, Madhusmita
A1 Gupta, Nishkarsh
A1 Garg, Rohit Kumar
A1 Paul, Saurav Sekhar
A1 Ratre, Brajesh Kumar
A1 Singh, Ram
A1 Kumar, Balbir
A1 Vig, Saurabh
A1 Pandit, Anuja
A1 Kumar, Abhishek
A1 Garg, Rakesh
A1 Meena, Ved Prakash
A1 Mittal, Saurabh
A1 Pahuja, Saurabh
A1 Das, Nupur
A1 Dwivedi, Tanima
A1 Gupta, Ritu
A1 Kumar, Sunil
A1 Pandey, Manisha
A1 Mishra, Abhinav
A1 Matharoo, Karanvir Singh
A1 Mohan, Anant
A1 Guleria, Randeep
A1 Bhatnagar, Sushma
YR 2021
UL http://medrxiv.org/content/early/2021/08/28/2021.08.26.21262668.abstract
AB Background Hypoxia in patients with COVID-19 is one of the strongest predictors of mortality. Silent hypoxia is characterized by the presence of hypoxia without dyspnea.. Silent hypoxia has been shown to affect the outcomes in previous studies.Research Question Are the outcomes in patients presenting with silent hypoxia different from those presenting with dyspneic hypoxia?Study design and Methods This was a retrospective study of a cohort of patients with SARS-CoV-2 infection who were hypoxic at presentation. Clinical, laboratory, and treatment parameters in patients with silent hypoxia and dyspneic hypoxia were compared. Multivariate logistic regression models were fitted to identify the factors predicting mortality.Results Among 2080 patients with COVID-19 admitted to our hospital, 811 patients were hypoxic with SpO2<94% at the time of presentation. 174 (21.45%) did not have dyspnea since the onset of COVID-19 symptoms. 5.2% of patients were completely asymptomatic for COVID-19 and were found to be hypoxic only on pulse oximetry. The case fatality rate in patients with silent hypoxia was 45.4% as compared to 40.03% in dyspneic hypoxic patients (P=0.202). The odds ratio of death was 1.1 (95% CI 0.41-2.97) in the patients with silent hypoxia after adjusting for baseline characteristics, laboratory parameters, treatment, and in-hospital complications, which did not reach statistical significance (P=0.851).Interpretation Silent hypoxia may be the only presenting feature of COVID-19. Since the case fatality rate is comparable between silent and dyspneic hypoxia, it should be recognized early and treated as aggressively. Since home isolation is recommended in patients with COVID-19, it is essential to use pulse oximetry at the home setting to identify these patients.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialRetrospective cohort studyFunding StatementNot ApplicableAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institute Ethics Committee, All India Institute of Medical Sciences, New DelhiAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be made available to others upon reasonable request to be routed through our Institute ethics committee with an appropriate protocol COVID-19Coronavirus diseaseHFNCHigh flow nasal cannulaIMVInvasive mechanical ventilationNIVNon-invasive ventilationSARS-CoV-2severe acute respiratory syndrome coronavirus 2SpO2Peripheral oxygen saturation